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Nitric oxide (NO) is an important molecule involved in nociceptive processing in the central nervous system. *e release of NO
within the spinal cord has long been implicated in the mechanisms underlying exaggerated pain sensitivity, and administration
of NO donors can induce hyperalgesia. To elucidate the supraspinal mechanism responsible for NO-induced nociceptive
hypersensitivity, we investigated the modulation of protein kinase C (PKC) and downstream e+ectors following treatment with the
NO donors nitroglycerin and sodium nitroprusside. Both compounds induced a prolonged cold allodynia and heat hyperalgesia,
increased levels of c-Fos and IL-1훽, and activated NF-휅B within periaqueductal grey matter and thalamus. Simultaneously, an
increased expression and phosphorylation of PKC 훾 and 휀 were detected. To clarify the cellular mechanism involved in the NO-
induced hypernociception, we examined the expression of transcription factors that act as PKC downstream e+ectors. A dramatic
hyperphosphorylation of CREB and STAT1 was observed. *e i.c.v. administration of the PKC blocker calphostin C prevented
the NO-induced hypernociception, the hyperphosphorylation of CREB and STAT1, and partially reduced NF-휅B activation.
Conversely, the increase of IL-1훽 was unmodi)ed by calphostin C. *ese results suggest the relevance of cerebral PKC-mediated
CREB and STAT1 activation in the NO donor-induced nociceptive behavior.
1. Introduction
Nitric oxide (NO) is a molecule importantly involved in
pain processing within central nervous system.*e release of
NO within the spinal cord has long been implicated in the
mechanisms underlying exaggerated pain sensitivity [1]. A
reduced nociceptive behavior was observed in in,ammatory
and neuropathic pain a-er intrathecal administration of NO
synthase (NOS) inhibitors [2, 3] and a-er genetic deletion
of the NOS isoforms [4–6]. In addition, NO donors induced
thermal [7] and mechanical [8] hyperalgesia.
Studies on the possible mechanism of action of NO and
subsequent steps in the NO-induced cascade show that NO
signals by various mechanisms including cGMP synthesis,
nitrosylation of ion channels, ADP-ribosylation, and the
interactionwithmolecular oxygen and superoxide radicals to
produce reactive nitrogen species that can modify a number
of macromolecules [9]. A major signaling mechanism of
NO in spinal nociceptive processing initiates with activation
of NO sensitive guanylyl cyclase and subsequent cGMP
production [10, 11]. It has been speculated that activation
of cGMP-dependent protein kinase I (cGKI), in turn, is
the major e+ector of NO-dependent cGMP synthesis in the
spinal cord [12, 13] and that the pronociceptive e+ects of the
NO are mediated by activation of cGKI [14, 15]. However,
the possible activation of targets di+erent from cGKI has
been postulated on the bases of data showing the lack of
antagonism of the pronociceptive e+ect of an NO donor by
the cGKI inhibitor [8]. Conversely to the spinal mechanisms,
little is known on the supraspinal events modulated by NO.
Protein kinase C (PKC) is a family of enzymes involved
in pain modulation. PKC integrates numerous receptor path-
ways into )nal e+ectors that increase excitatory signaling
and decrease inhibitory signaling, thus inducing pain [16].
Recently, it has been reported that PKC inhibitors reduce
NO synthesis from IFN-훾-treated microglia and that speci)c
PKC isoforms (i.e., 훿) are able to regulate NF-휅B activation
and iNOS expression in mouse peritoneal macrophages [17,
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18]. We, hence, aimed to investigate the involvement of
PKC isoforms in the nociceptive behavior induced by NO
donors’ administration. To better elucidate the NO signaling
cascade, we detected the expression of the main downstream
PKC e+ectors in the early and delayed events produced by
NO donors. In the brain, NO has been proposed to be
involved in synaptic plasticity or to act as a neurotoxin
when produced in excess [19], but its cerebral role in pain
modulation is not completely understood. We, then, focused
on supraspinal events induced by administration of the
NO donors nitroglycerin (GTN) and sodium nitroprusside
(SNP), and experiments were conducted in brain areas
involved in painmodulation, such as thalamus and periaque-
ductal grey matter.
2. Materials and Methods
2.1. Animals. Male Swiss albino mice (20–22 g) from the
Morini (San Polo d’Enza, Italy) breeding farm were used.
Ten mice were housed per cage (26 × 41 cm). *e cages
were placed in the experimental room 24 h before the test
for habituation. *e animals were fed a standard laboratory
diet and tap water ad libitum and kept at 23 ± 1∘C with a
12 h light/dark cycle, light on at 7 a.m. All experiments were
carried out in accordance with the European Communities
Council Directive of 24 November 1986 (86/609/EEC). All
e+orts weremade tominimize animal su+ering and to reduce
the number of animals used.
2.2. Behavioral Testing. Animals were habituated to the
experimental room and were investigated by observers
blinded for treatment of the animals.
2.2.1. Cold Plate. For assessment of cold allodynia, mice were
placed on a cold plate that is maintained at a temperature of
4 ± 0.1∘C. Reaction times (s) were measured with a stopwatch
before and 1, 2, 4, and 6 h a-er administration of the NO
donors.*e time between placements of amouse on the plate
and licking or li-ing of a hind paw was measured with a
digital timer. An arbitrary cut-o+ time of 60 s was adopted.
2.2.2. Hot Plate. Mice were placed inside a stainless steel
container, which was set thermostatically at 50.0 ± 0.1∘C in
a precision water-bath (KW Mechanical Workshop, Siena,
Italy). Reaction times (s) were measured with a stopwatch
before and 1, 2, 4, and 6 h a-er administration of the NO
donors.*e endpoint used was the licking of the fore or hind
paws. An arbitrary cut-o+ time of 60 s was adopted.
2.2.3. Motor Coordination. *e motor coordination was
assessed by using the rota rod test. *e apparatus consisted
of a base platform and a rotating rod with a diameter of 3 cm
and a nonslippery surface. *e rod was placed at a height
of 15 cm from the base.*e rod, 30 cm in length, was divided
into 5 equal sections by 6 disks.*us, up to 5mice were tested
simultaneously on the apparatus, with a rod-rotating speed of
16 r.p.m.*e integrity of motor coordination was assessed on
the basis of the number of falls from the rod in 30 s. *ose
mice scoring less than 3 and more than 6 falls in the pretest
were rejected (20%).*e number of falls wasmeasured before
(pretest) and 2, 4, and 6 h a-er the administration of the NO
donors.
2.2.4. Locomotor Activity. *e locomotor activity was evalu-
ated by using the hole-board test.*e apparatus consisted of
a 40 cm square plane with 16 ,ush mounted cylindrical holes
(3 cm diameter) distributed 4 by 4 in an equidistant, grid-like
manner. Mice were placed on the center of the board one-by-
one and allowed to move about freely for a period of 5min
each. Two photobeams, crossing the plane from midpoint
to midpoint of opposite sides, thus dividing the plane into
4 equal quadrants, automatically signaled the movement of
the animal (counts in 5min) on the surface of the plane
(locomotor activity). Miniature photoelectric cells, in each of
the 16 holes, recorded (counts in 5min) the exploration of the
holes (exploratory activity) by the mice. Experiments were
performed 4 h a-er administration of the NO donors.
2.3. Western Blot Experiments. Experiments were conducted
on PAG and thalamus of naı¨ve, vehicle-, GTN-, or SNP-
treated mice.
2.3.1. Preparation of Whole Cell Lysates, Membranes, and
Cytosol Fractions. Mice were perfused transcardially with
0.9% NaCl. Brain areas to conduct western blotting exper-
iments were collected 1, 2, 4, and 6 h a-er the GTN
(10mg/kg i.p.) or SNP (1mg/kg i.p.) treatment. Mouse brains
were dissected to separate speci)c areas. PAG and thalamus
were homogenized in an homogenization bu+er containing
25mMTris-HCl pH= 7.5, 25mMNaCl, 5mMEGTA, 2.5mM
EDTA, 2mMNaPP, 4mMPNFF, 1mMNa3VO4, 1mMPMSF,
20휇g/mL leupeptin, 50 휇g/mL aprotinin, and 0.1% SDS.*e
homogenate was centrifuged at 9,000×g for 15min at 4∘C; the
low speed pellet was discarded. *e supernatant (whole cell
lysate) was centrifuged at 100,000×g for 60min at 4∘C. *e
resulting supernatant was the cytosol fraction, and the pellet
was resuspended in the homogenizing bu+er containing 0.2%
(wt/vol) Triton X-100. *e homogenate was kept at 4∘C
for 60min with occasional stirring and then centrifuged
at 100,000×g for 60min at 4∘C. *e resultant supernatant
was used as membrane fraction. Protein concentration was
quanti)ed using Bradford’s method (protein assay kit, Bio-
Rad Laboratories, Milan, Italy).
2.3.2. Western Blot Analysis. Membrane homogenates (10–
50 휇g) made from PAG and thalamus regions of GTN-,
SNP-, vehicle-treated and na¨ıve mice were separated on 10%
SDS-PAGE and transferred onto nitrocellulose membranes
(90min at 120V) using standard procedures. Membranes
were blocked in PBST (PBS containing 0.1% Tween) con-
taining 5% nonfat dry milk for 120min. Following washings,
blots were incubated overnight at 4∘Cwith speci)c antibodies
against PKC훾 phosphorylated on *r514 (pPKC훾, 1 : 1000
dilution), c-Fos (1 : 1000) (Biosource, Camarillo, CA, USA);
PKC훾 (1 : 1000); PKC휀 (1 : 800); PKC휀 phosphorylated on
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Ser729 (pPKC휀, 1 : 750); iNOS (1 : 250); STAT1 phosphory-
lated on Tyr701 (pSTAT1, 1 : 500); 훽-actin (1 : 1000 dilution)
(Santa Cruz Biothechnology Inc, CA, USA); CREB (1 : 500)
or CREB phosphorylated on Ser133 (pCREB, 1 : 500) (cell Sig-
nalling Technology). A-er beingwashedwith PBS containing
0.1% Tween, the nitrocellulose membrane was incubated
with goat anti-rabbit horseradish peroxidase-conjugated sec-
ondary antisera (1 : 10,000) and le- for 1 h at room temper-
ature. Blots were then extensively washed according to the
manufacturer’s instruction and developed using enhanced
chemiluminescence detection system (Pierce, Milan, Italy).
Exposition and developing time used was standardized for
all the blots. Optical density measurements were performed
by dividing the intensity of the bands by the intensity of the
house-keeping protein 훽-actin or GAPDH, used as loading
control, at each time point. Measurements in control samples
were assigned a relative value of 100%.
2.4. Animal Treatment. *e NO donors nitroglycerin (glyc-
eryl trinitrate (GNT)) (Bioindustria L.I.M., Italy), dissolved
in 10% ethylene glycol in saline (0.9% NaCl), and sodium
nitroprusside (SNP) (Sigma, Italy), dissolved in saline, were
administered intraperitoneally (i.p.).
To investigate the role of PKC in the intracellular events
modulated by NO donors, the PKC blocker calphostin C
(Calbiochem, Milan, Italy) was used. Time-course exper-
iments performed in our laboratory showed that the
calphostin C e+ect peaked 1-2 h a-er intracerebroventricular
(i.c.v.) administration. Animals were, then, divided into
di+erent treatment groups.
2.4.1. Behavioral Testing. Vehicle, GTN, or SNP were i.p.
administered, and pain thresholdwas evaluated 1 and 2 h a-er
treatment. Following NO donors’ administration, animals
received a single i.c.v. injection of vehicle (0.5% DMSO)
or calphostin C (0.2휇g per mouse) 3 h a-er GNT or SNP
treatment. *e pain threshold was, then, evaluated at 4 h,
in coincidence with the maximal hypernociceptive activity
of NO donors, and at 6 h when the nociceptive behavior
disappeared.
2.4.2. Western Blot. Brain areas samples to perform experi-
ments were removed 1, 2, 4, and 6 h a-er NO donors’ admin-
istration. Animals were divided in two groups of treatment:
(1) vehicle (0.5%DMSO) or calphostinC administered 10min
before NO donors injection and protein expression detected
2 h a-er GNT/SNP administration; (2) vehicle (0.5%DMSO)
or calphostin C administered 3 h a-erNOdonors and protein
expression detected 4 h a-er GNT/SNP.
Aspirin 40mg/kg (Bayer AG, Leverkusen, Germany) was
dissolved in 0.5% DMSO and administered i.p. 3 h a-er NO
donor injection. Brain samples were collected at 4 h.
Lipopolysaccharide (LPS) (60mg/kg ip, Sigma, Italy) was
used as positive control of IL-1훽 expression. Brain areas to
conduct experiments were removed 6 h a-er LPS adminis-
tration.
Intracerebroventricular (i.c.v.) administration was per-
formed as previously described [20].
2.5. Statistical Analysis. Behavioral experiments results were
given as mean ± SD. 10 mice per group were used. Two-
way analysis of variance (ANOVA) followed by Bonferroni
post hoc test was used for statistical analysis. Western blotting
experimental results were given as the mean ± SEM of results
obtained from 6–8 independent experiments. Analysis of
variance (ANOVA) followed by Tukey post hoc test was used
for statistical analysis.
3. Results
3.1. Nociceptive Hypersensitivity without Induction of Side Ef-
fects by NODonors. *e administration of SNP (0.5–2mg/kg
i.p.; Figure 1(a)) and GTN (1–10mg/kg i.p.; Figure 1(b))
induced cold allodynia as revealed by the cold plate test. Time
course studies showed a prolonged nociceptive behavior.*e
reaction times to the cold stimulus were reduced 1, 2, and
4 h a-er NO donors’ administration. *e pain threshold
returned to control values 6 h a-er SNP (Figure 1(c)) or GNT
(Figure 1(d)) injection. Following NO donor treatment, a
thermal hyperalgesia was also observed in the hot plate test
with a time course similar to the cold allodynia. Mice showed
reduced licking latency values 2 and 4 h a-er administration
whereas at 6 h the hyperalgesic e+ect disappeared (Figures
1(e) and 1(f)).
*e reduction of the pain threshold was not accompanied
by the induction of side e+ects. NO donors did not alter
locomotor activity of treated animals at any time point, as
indicated by the rota rod test results (Figure 1(g)).*e spon-
taneous mobility (SM) and exploratory activity (EA) of mice
treated with SNP and GTN were unmodi)ed in comparison
with the control group (hole board test; Figure 1(h)).
3.2. Blockade of PKC Phosphorylation Prevented NO Donor-
Induced Nociceptive Behavior. *e i.c.v. injection of the PKC
blocker calphostin C (calph; 0.2휇g per mouse) completely
reversed the hypersensitivity to cold (Figure 2(a)) and heat
(Figure 3(b)) stimuli induced by SNP leading to reaction
times comparable to control values. Similar results were
produced by GTN. Calphostin C, when administered alone,
did not alter the mouse pain threshold suggesting the lack of
any hyperalgesic/analgesic activity (Figures 2(a) and 2(b)).
NO donors increased the levels of phosphorylated PKC훾
(Figure 2(c)) and PKC휀 (Figure 2(d)) within PAG and tha-
lamus membrane fraction with a peak 2–4 h a-er treat-
ment. Total PKC훾 and PKC휀 protein expressions were also
increased 2 and 4 h a-er treatment with a similar time course
for GTN and SNP.
Calphostin C prevented the upregulation of pPKC훾 and
pPKC휀, indicating that the doses and administration schedule
of calphostin C used in behavioral tests were ideal to block
PKC activity.
Vehicles did not modify protein expression in compari-
son with na¨ıve animals’ protein content.
3.3. NO Donors Induced IL-1훽 Upregulation and NF-휅B Ac-
tivation. To evaluate the supraspinal mediators involved in
the induction of the NO-induced nociceptive behavior, we
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Figure 1: NO donors decrease the pain threshold without behavioral side e+ects. Administration of sodium nitroprusside (SNP, 0.5–
2mg/kg i.p.) (a) or nitroglycerin (GTN, 1–10mg/kg i.p.) (b) induced cold allodynia, evaluated in the cold plate test. ∗∗∗푃 < 0.001 compared
with before administration values. Time course studies showed a prolonged cold allodynia (c, d) and heat hyperalgesia, evaluated in the hot
plate test (e, f) that disappeared 6 h a-er injection. GTN (10mg/kg) and SNP (1mg/kg) did not alter motor coordination (rota rod test) (g),
spontaneous mobility, and inspection activity (hole board test) (h). ∗푃 < 0.05, ∗∗푃 < 0.01, ∗∗∗푃 < 0.001 compared with vehicle-treated
mice (VEH).
examined the expression of cellular components involved
in in,ammatory processes. In particular, IL-1훽 and NF-휅B
were detected in homogenates of PAG and thalamus a-er
administration of NO donors by immunoblotting technique.
GTN and SNP induced a progressive increase of IL-1훽
up to 4 h a-er administration whereas at 6 h the IL-1훽
levels decreased. *e maximal increase of IL-1훽 expression
was comparable to that produced by LPS, used as positive
control. A similar expression pro)le was detected in the PAG
(Figure 3(a)) and thalamus (Figure 3(b)).
*e activation of the NF-휅B pathway was demonstrated
by the reduction of the I휅-B훼 expression, the protein
that constitutively inhibits NF-휅B. *e decrease of I휅-B훼
peaked 1 h a-er administration with a prolonged e+ect,
being signi)cant up to 4 h a-er NO donors’ administration
(Figures 3(c) and 3(d)).
c-Fos has been widely used as a marker of neuronal
activation and pain. To further support the hypothesis of a
supraspinal mechanism for the induction of a nociceptive
behavior byNO, we detected the c-Fos protein content within
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Figure 2: Allodynia and hyperalgesia produced byNOdonors’ administration underly a PKC-mediated pathway.*e PKCblocker calphostin
C (calph; 0.2 휇g permouse i.c.v.) reversed cold allodynia (a) and heat hyperalgesia (b) induced by SNP. Calphostin C (c) completely prevented
the SNP-induced upregulation of pPKC훾 (c) and pPKC휀 (d) within PAG and thalamus. ∗푃 < 0.05, ∗∗푃 < 0.01, ∗∗∗푃 < 0.001 compared with
vehicle-treated control group; ∘푃 < 0.05, ∘∘푃 < 0.001 compared with SNP-treated group.
PAG and thalamus, brain areas related to pain perception.
A rapid and progressive increase of c-Fos expression within
the PAG was observed a-er GTN and SNP administration
(Figure 3(e)). Similarly, a robust increase of the c-Fos expres-
sion was detected 2 and 4 h a-er NO donor treatments within
the thalamus (Figure 3(f)).
No di+erence between GTN and SNP was observed.
Vehicles used did not modify the protein expression when
compared with na¨ıve animals’ protein content.
3.4. Activation of CREB following NO Donors. GNT and
SNP produced a drastic decrease of CREB levels in the
whole cell lysates from PAG (Figure 4(a)). *e reduction of
CREB expression was evident 1 and 2 h a-er NO donors’
administration; then the levels increased and returned to
control values. A reduction of CREB protein content was also
observed in the thalamus but with a slightly di+erent time
course: the decrease of the protein content was signi)cant 2 h
a-er administration, peaked at 4 h, and returned to control
values at 6 h (Figure 4(b)). No di+erence between the e+ects
produced by GTN and SNP was observed.
A robust increase of the phosphorylated form of CREB
(pCREB) was detected in the total cell lysate from PAG
(Figure 4(c)).*is e+ect was signi)cant 1 h a-er administra-
tion and peaked between 2 and 4 h, and then it drastically
decreased. Similar results were obtained from experiment
conducted on the total cell lysates from the thalamus
(Figure 4(d)).
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Figure 3: Cerebral modulation of IL-1훽 and NF-휅B by NO donors. GNT and SNP increased the expression of IL-1훽 within PAG (a) and
thalamus (b) with a peak at 4 h a-er administration. LPS was used as positive control. NO donors produced a cerebral activation of the NF-휅B pathway as indicated by the reduction of I휅-B훼 levels in the PAG (c) and thalamus (d). NO donors increased c-Fos protein levels in the
PAG (c) and thalamus (d) with a similar time course to the nociceptive hypersensitivity. ∗푃 < 0.05, ∗∗푃 < 0.01, ∗∗∗푃 < 0.001 compared with
vehicle-treated control group (c).
Vehicles used did not modify protein expression when
compared with na¨ıve animals’ protein content.
3.5. GTN and SNP Induced STAT1 Overexpression. A highly
signi)cant increase in the phosphorylated form of STAT1
(pSTAT1)was detected in the PAG (Figure 4(e)) and thalamus
(Figure 4(f)) of SNP- and GTN- (data not shown) treated
animals.*e pSTAT1 contents increased 1 h a-er SNP admin-
istration and peaked at 4 h, and 6 h a-er treatment pSTAT1
levels returned comparable to control. In the thalamus
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Figure 4: NO donors modulated CREB and STAT1 expression and phosphorylation. GNT and SNPmodulated cerebral CREB protein levels
as indicated by the CREB downregulation within PAG lysate (a) and thalamus (b). An upregulation of phosphorylated CREB (pCREB)
following NO donors’ administration was observed in the PAG (c) and thalamus (d). NO donors induced upregulation of phosphorylated
STAT1 (pSTAT1). pSTAT1 protein levels were increased 1, 2 and 4 h a-er SNP treatment within PAG (e) and thalamus (f). ∗푃 < 0.05, ∗∗푃 <0.01, ∗∗∗푃 < 0.001 compared with vehicle-treated control group (c).
the increase of the pSTAT1 expression showed a similar time
course to the PAG, but the increase of pSTAT1 was greater
than in the PAG.
No di+erence between the e+ects produced by GTN
and SNP was observed. Vehicles used did not modify pro-
tein expression when compared with na¨ıve animals’ protein
content.
3.6. NO Donors Induce Allodynia and Hyperalgesia through
a PKC-Dependent Mechanism. To investigate whether the
cellular components modulated by NO donors represented
downstream e+ectors of PKC, we detected their expression
following calphostin C administration. *e expression of
IL-1훽 was unmodi)ed by the PKC blocker whereas it was
reduced by aspirin (ASA) in both cerebral areas (Figure 5(a)).
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Figure 5: Activation of a PKC-independent and a PKC-mediated pathway by NO donors. (a) SNP-induced increase of IL-1훽 within PAG
and thalamus (THAL) was unmodi)ed by pretreatment with the calphostin C and prevented by aspirin (ASA). (b) *e reduction of I휅-B훼
was partially prevented by calphostin C and completely restored by ASA. Calphostin C antagonized the downregulation of CREB (c) and
prevented the increased expression of pCREB (d) and pSTAT1 (e). ∗푃 < 0.05, ∗∗푃 < 0.01, ∗∗∗푃 < 0.001 compared with vehicle-treated
control group; ∘푃 < 0.05, ∘∘푃 < 0.01 compared with SNP-treated group.
*e reduced levels of I휅-B훼 were only partially restored by
calphostin C whereas ASA completely prevented the NF-휅B activation (Figure 5(b)). Conversely, the modulation of
CREB and STAT1 expression was PKC-mediated. Treatment
with calphostin C completely reversed the SNP-induced
decrease of CREB protein levels (Figure 5(c)) and increase of
pCREB (Figure 5(d)) and pSTAT1 within PAG and thalamus
(Figure 5(e)). Calphostin C prevented the modulation of the
expression of CREB, pCREB, and STAT1 1, 2, and 4 h a-er
NO donors’ administration. No e+ect was detected at 6 h
where the levels of the above-mentioned proteins returned to
control values.
4. Discussion
*e systemic administration of the NO donors GTN and
SNP in mice produced cold allodynia and heat hyperalgesia
detectable 1 h a-er administration that peaked at 4 h. *ese
results con)rm and extend previous studies that described
the induction of thermal hyperalgesia in rats a-er systemic
administration of GTN with a similar time course [7].
To elucidate the mechanism responsible for the produc-
tion of hyperalgesia, we investigated the role of the protein
kinase C (PKC), a family of enzymes highly involved in pain
modulation [16]. I.c.v. administration of the PKC blocker
calphostin C prevented the NO donor-induced allodynia and
hyperalgesia producing pain threshold values similar to those
of the na¨ıve animals.
To evaluate the site of the pronociceptive action of NO
donors, we detected the PKC expression within PAG and
thalamus, cerebral areas highly involved in themodulation of
pain perception. In GTN- and SNP- treated mice we detected
a speci)c upregulation and increased phosphorylation of
PKC휀 and PKC훾, isoforms with a prominent role in the
modulation of pain perception [16, 21, 22], concomitantly
with the presence of allodynia and pain. It is known that
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PKC represents a second messenger pathway coupled to the
induction of c-Fos, the protein product of the immediate early
gene c-fos, widely used as marker of neuronal activation.*e
evaluation of the time-course of the c-Fos expression revealed
a correspondence between c-Fos levels and the nociceptive
behavior. Since c-Fos is also used asmarker of pain [23], these
results further con)rm the presence of a neuronal activation
related to the pain hypersensitivity detected by in vivo studies.
*ese results have highlighted the importance of PKC in the
nociceptive behavior induced by NO donors.
When can, therefore, hypothesize the presence of a
PKC-mediated intracellular pathway activated by NO and
responsible for the nociceptive behavior. To elucidate this
pathway, we investigated PKC downstream e+ectors that
might be involved in the induction of pain hypersensitivity,
such as CREB and STAT1. CREB is a ubiquitously and
constitutively expressed transcription factor. Its ability to
activate transcription of the regulated gene critically depends
on phosphorylation of a serine residue, Ser133, in its trans-
activation domain [24]. We detected a relevant in,uence on
CREB phosphorylation by GTN and SNP. A robust increase
in the phosphorylation of CREB has been observed in the
PAG and thalamus with a peak at 2–4 h a-er GTN and SNP
treatment, in coincidence with the presence of allodynia and
hyperalgesia. *e pCREB expression appeared to be PKC
dependent since the PKC blocker calphostin C prevented
the NO donors’ modulation of this transcription factor.
NO-induced CREB phosphorylation might contribute to the
genesis of the hypersensitivity to noxious stimuli observed
following NO donors’ administration. *is hypothesis is
supported by observations that highlight a role for CREB
in the modulation of pain sensation. In the early stages
of in,ammation [25] and sciatic nerve injury [26], the
phosphorylation of CREB is increased in the dorsal horn
through a mechanism involving several kinases, including
PKC [27].
A dramatic increase in the expression of the phosphory-
lated form of STAT1 (pSTAT1) was observed following NO
donors’ injection. Within PAG and thalamus the pSTAT1
upregulation was detected beginning from 1 h up to 4 h
a-er NO donors’ administration. We can hypothesize an
important role for STAT1 as cellular e+ector for NO donors.
PKC appears to be an upstreammodulator of STAT1 since the
PKC blocker calphostin C completely prevented the pSTAT1
increase.*is hypothesis is supported by the observation that
inhibition of classical PKC isoenzymes downregulate STAT1
activation in LPS-treated murine macrophages [28].
Many animal studies have shown that NO contributes to
the sensitization during in,ammatory pain. We, therefore,
detected the supraspinal expression of important mediators
of in,ammation to determine their role in the NO-induced
nociceptive behavior. GTN and SPN produced a progressive
increase of IL-1훽 protein levels and activation of NF-휅B,
as demonstrated by the reduction of I휅-B훼 protein levels.
Conversely to CREB and STAT1, these mediators appeared
not to be main PKC downstream e+ectors since pretreatment
with the PKC blocker calphostin C did not modify IL-1훽
levels and only partially reduced I휅-B훼 protein levels. Since
calphostin C completely prevented the NO donor-induced
nociceptive behavior, we can exclude a major role for IL-1훽
and NF-휅B in the cerebral mechanisms responsible for the
induction pain hypersensitivity.
Although GTN can accumulate and reach toxic levels in
adipose tissue and lipid-rich organs such as brain, we can
exclude that the hypersensitivity observed was related to an
altered viability of mice. NO donors did not modify spon-
taneous mobility, inspection activity, and locomotor activity
and were not endowed with visible behavioral side e+ects
at any time point. As regards cardiovascular e+ect, both
GTN and SNP systemically administered at the doses used in
the present study induced moderate hypotension that lasted
40 and 80min, respectively [29]. No altered cardiovascular
parameter was observed 2 and 4 h a-er treatment [29], and
we can suppose that pain hypersensitivity was not subsequent
to a hypotensive e+ect.
*ese )ndings highlight the upregulation and increased
phosphorylation of PKC훾 and PKC휀 as cerebral intracellular
mechanism involved in the induction of pain hypersensi-
tivity following NO donors’ administration. *e presence
of a PKC-mediated pathway involving STAT1 and CREB
as PKC downstream e+ectors has also been demonstrated.
*ese cellular events were detected concomitantly with the
presence of allodynia and hyperalgesia suggesting that these
transcription factors might act synergistically to modulate
pain perception.
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